"Macular Degeneration" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.
| Descriptor ID |
D008268
|
| MeSH Number(s) |
C11.768.585.439
|
| Concept/Terms |
Macular Degeneration- Macular Degeneration
- Degeneration, Macular
- Degenerations, Macular
- Macular Degenerations
- Age-Related Maculopathies
- Age Related Maculopathies
- Macular Degeneration, Age-Related
- Macular Dystrophy
- Dystrophies, Macular
- Dystrophy, Macular
- Macular Dystrophies
- Maculopathies, Age-Related
- Maculopathies, Age Related
- Maculopathy, Age-Related
- Maculopathy, Age Related
- Age-Related Macular Degeneration
- Age Related Macular Degeneration
- Age-Related Macular Degenerations
- Degeneration, Age-Related Macular
- Degenerations, Age-Related Macular
- Macular Degenerations, Age-Related
- Age-Related Maculopathy
- Age Related Maculopathy
|
Below are MeSH descriptors whose meaning is more general than "Macular Degeneration".
Below are MeSH descriptors whose meaning is more specific than "Macular Degeneration".
This graph shows the total number of publications written about "Macular Degeneration" by people in this website by year, and whether "Macular Degeneration" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 1 | 3 |
| 2014 | 4 | 1 | 5 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 1 | 1 | 2 |
| 2018 | 4 | 0 | 4 |
| 2019 | 6 | 0 | 6 |
| 2020 | 2 | 0 | 2 |
| 2021 | 10 | 0 | 10 |
| 2022 | 7 | 0 | 7 |
| 2023 | 14 | 1 | 15 |
| 2024 | 4 | 3 | 7 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Macular Degeneration" by people in Profiles.
-
A deconvolution framework that uses single-cell sequencing plus a small benchmark data set for accurate analysis of cell type ratios in complex tissue samples. Genome Res. 2025 Jan 22; 35(1):147-161.
-
Photobiomodulation Therapy for Non-exudative Age-related Macular Degeneration. Int Ophthalmol Clin. 2025 Jan 01; 65(1):47-52.
-
QM107, a novel CD148 (RTP Type J) activating peptide therapy for treating neovascular age-related macular degeneration. Br J Pharmacol. 2025 Feb; 182(4):951-968.
-
Development of Microcystoid Macular Degeneration in the Retina of Nonhuman Primates: Time-Course and Associated Pathologies. Curr Eye Res. 2025 Jan; 50(1):93-100.
-
Risk factors for development of hyper-reflective foci overlying drusen in eyes with intermediate age-related macular degeneration. Br J Ophthalmol. 2024 Aug 22; 108(9):1234-1239.
-
Spectral-domain OCT characteristics of intraretinal hyper-reflective foci associated with age-related macular degeneration and diabetic retinopathy. Can J Ophthalmol. 2025 Apr; 60(2):91-99.
-
Quantifying Geographic Atrophy in Age-Related Macular Degeneration: A Comparative Analysis Across 12 Deep Learning Models. Invest Ophthalmol Vis Sci. 2024 Jul 01; 65(8):42.
-
PARACENTRAL ACUTE MIDDLE MACULOPATHY IN GIANT CELL ARTERITIS. Retin Cases Brief Rep. 2024 May 01; 18(3):285-289.
-
Acquired Vitelliform Lesions in Intermediate Age-Related Macular Degeneration: A Cross Sectional Study. Ophthalmol Retina. 2024 Sep; 8(9):854-862.
-
Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization. Biomolecules. 2024 Feb 21; 14(3).